Inovio Pharmaceuticals Inc. (INO) Given Average Rating of “Buy” by Analysts
Inovio Pharmaceuticals Inc. (NASDAQ:INO) has received an average rating of “Buy” from the nine brokerages that are presently covering the company. Two investment analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $13.59.
A number of equities analysts have recently commented on the company. Vetr cut Inovio Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $11.11 price target for the company. in a report on Monday, August 1st. Piper Jaffray Cos. reissued an “overweight” rating and set a $31.00 price target on shares of Inovio Pharmaceuticals in a report on Monday, August 8th. Brean Capital assumed coverage on Inovio Pharmaceuticals in a report on Tuesday, October 4th. They set a “buy” rating and a $18.00 price target for the company. Zacks Investment Research raised Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, September 26th. Finally, Maxim Group cut Inovio Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, August 9th.
In related news, COO Niranjan Sardesai sold 21,800 shares of the business’s stock in a transaction on Monday, August 29th. The stock was sold at an average price of $9.30, for a total transaction of $202,740.00. Following the sale, the chief operating officer now owns 70,234 shares in the company, valued at approximately $653,176.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 9.90% of the company’s stock.
A number of large investors have recently modified their holdings of INO. Cetera Advisors LLC raised its stake in shares of Inovio Pharmaceuticals by 8.7% in the third quarter. Cetera Advisors LLC now owns 30,166 shares of the biopharmaceutical company’s stock worth $281,000 after buying an additional 2,410 shares in the last quarter. Panagora Asset Management Inc. raised its stake in Inovio Pharmaceuticals by 9.3% in the third quarter. Panagora Asset Management Inc. now owns 398,888 shares of the biopharmaceutical company’s stock worth $3,718,000 after buying an additional 33,776 shares during the period. The Manufacturers Life Insurance Company bought a new stake in Inovio Pharmaceuticals during the third quarter worth approximately $426,000. Morgan Stanley raised its stake in Inovio Pharmaceuticals by 7.9% in the third quarter. Morgan Stanley now owns 604,867 shares of the biopharmaceutical company’s stock worth $5,637,000 after buying an additional 44,055 shares during the period. Finally, Principal Financial Group Inc. raised its stake in Inovio Pharmaceuticals by 1.8% in the third quarter. Principal Financial Group Inc. now owns 11,885 shares of the biopharmaceutical company’s stock worth $111,000 after buying an additional 208 shares during the period. Institutional investors and hedge funds own 27.91% of the company’s stock.
Inovio Pharmaceuticals (NASDAQ:INO) traded down 0.4825% during trading on Monday, reaching $7.9415. The company had a trading volume of 339,456 shares. The firm’s market capitalization is $588.15 million. The firm’s 50 day moving average price is $7.89 and its 200 day moving average price is $9.18. Inovio Pharmaceuticals has a 12-month low of $4.50 and a 12-month high of $11.69.
Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings data on Wednesday, November 9th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by $0.02. The company earned $12.54 million during the quarter, compared to analyst estimates of $5.16 million. Inovio Pharmaceuticals had a negative net margin of 199.99% and a negative return on equity of 39.93%. Inovio Pharmaceuticals’s revenue was down 48.3% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.08) earnings per share. Analysts anticipate that Inovio Pharmaceuticals will post ($0.96) earnings per share for the current year.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc (Inovio) is a bio-pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
Receive News & Stock Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.